MLECW vs. CHRS

Last updated Jun 4, 2026

MLECW (Moolec Science SA Warrant) and CHRS (Coherus BioSciences, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, MLECW returned -34.96%/yr vs -30.87%/yr for CHRS. At a correlation of -0.03, they often move in opposite directions.

Performance

MLECW vs. CHRS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moolec Science SA Warrant (MLECW) and Coherus BioSciences, Inc. (CHRS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MLECW achieves a 268.98% return, which is significantly higher than CHRS's 3.52% return.

MLECW

• 1D: 26.63%
• 1M: -6.95%
• YTD: 268.98%
• 6M: 76.87%
• 1Y: 122.93%
• 3Y*: -34.96%
• 5Y*: —
• 10Y*: —

CHRS

• 1D: -3.29%
• 1M: -15.03%
• YTD: 3.52%
• 6M: 20.49%
• 1Y: 87.98%
• 3Y*: -30.87%
• 5Y*: -35.60%
• 10Y*: -22.28%

*Multi-year figures are annualized to reflect compound growth (CAGR)

MLECW vs. CHRS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
MLECW Moolec Science SA Warrant	268.98%	-77.17%	15.45%	-89.52%
CHRS Coherus BioSciences, Inc.	3.52%	2.90%	-58.56%	-60.87%

Correlation

The correlation between MLECW and CHRS is -0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.06
Correlation (3Y) Calculated over the trailing 3-year period	-0.03
Correlation (All Time) Calculated using the full available price history since Jan 4, 2023	-0.03

Fundamentals

Total Revenue (TTM) MLECW : $7.83M CHRS : $46.88M
Gross Profit (TTM) MLECW : -$639.50K CHRS : $23.41M
EBITDA (TTM) MLECW : -$5.21M CHRS : -$162.15M

Return for Risk

MLECW vs. CHRS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MLECW

MLECW Risk / Return Rank: 74
MLECW Sharpe Ratio Rank: 56
MLECW Sortino Ratio Rank: 90
MLECW Omega Ratio Rank: 88
MLECW Calmar Ratio Rank: 71
MLECW Martin Ratio Rank: 65

CHRS

CHRS Risk / Return Rank: 72
CHRS Sharpe Ratio Rank: 73
CHRS Sortino Ratio Rank: 72
CHRS Omega Ratio Rank: 69
CHRS Calmar Ratio Rank: 75
CHRS Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MLECW vs. CHRS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Moolec Science SA Warrant (MLECW) and Coherus BioSciences, Inc. (CHRS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MLECW	CHRS	Difference
Sharpe ratio Return per unit of total volatility	0.41	1.09	-0.68
Sortino ratio Return per unit of downside risk	3.21	1.85	+1.36
Omega ratio Gain probability vs. loss probability	1.41	1.22	+0.19
Calmar ratio Return relative to maximum drawdown	1.63	2.13	-0.50
Martin ratio Return relative to average drawdown	2.76	3.95	-1.19
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MLECW vs. CHRS - Sharpe Ratio Comparison

The current MLECW Sharpe Ratio is 0.41, which is lower than the CHRS Sharpe Ratio of 1.09. The chart below compares the historical Sharpe Ratios of MLECW and CHRS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MLECW	CHRS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.41	1.09	-0.68
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.42	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.30	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.16	-0.23	+0.07

Drawdowns

MLECW vs. CHRS - Drawdown Comparison

The maximum MLECW drawdown since its inception was -97.82%, roughly equal to the maximum CHRS drawdown of -98.21%. Use the drawdown chart below to compare losses from any high point for MLECW and CHRS.

Drawdown Indicators

	MLECW	CHRS	Difference
Max Drawdown Largest peak-to-trough decline	-97.82%	-98.21%	+0.39%
Max Drawdown (1Y) Largest decline over 1 year	-75.63%	-41.43%	-34.20%
Max Drawdown (3Y) Largest decline over 3 years	-94.66%	-87.71%	-6.95%
Max Drawdown (5Y) Largest decline over 5 years	—	-96.47%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-97.88%	—
Current Drawdown Current decline from peak	-90.27%	-96.08%	+5.81%
Average Drawdown Average peak-to-trough decline	-79.43%	-63.48%	-15.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	44.77%	22.36%	+22.41%

Volatility

MLECW vs. CHRS - Volatility Comparison

Moolec Science SA Warrant (MLECW) has a higher volatility of 44.33% compared to Coherus BioSciences, Inc. (CHRS) at 21.11%. This indicates that MLECW's price experiences larger fluctuations and is considered to be riskier than CHRS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MLECW	CHRS	Difference
Volatility (1M) Calculated over the trailing 1-month period	44.33%	21.11%	+23.22%
Volatility (6M) Calculated over the trailing 6-month period	214.82%	60.22%	+154.60%
Volatility (1Y) Calculated over the trailing 1-year period	300.75%	81.15%	+219.60%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	304.70%	84.64%	+220.06%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	304.70%	74.90%	+229.80%

Dividends

MLECW vs. CHRS - Dividend Comparison

Neither MLECW nor CHRS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MLECW and CHRS in my portfolio?

MLECW and CHRS have a correlation of -0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MLECW or CHRS?

MLECW has higher volatility (44.33%) compared to CHRS (21.11%). In terms of maximum drawdown, MLECW dropped -97.82% vs CHRS's -98.21%.

Which has better risk-adjusted returns?

CHRS currently has the higher Sharpe Ratio (1.09 vs 0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.